NASDAQ:PRTAProthena Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Prothena Co. PLC Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $12.55 -0.21 (-1.65 %) (As of 08/4/2020 04:00 PM ET) Add Compare Share Today's Range$12.32Now: $12.55▼$12.8050-Day Range$9.67MA: $11.37▼$13.4752-Week Range$6.71Now: $12.55▼$17.63Volume98,912 shsAverage Volume305,764 shsMarket Capitalization$500.87 millionP/E RatioN/ADividend YieldN/ABeta1.86 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a antibody that is in Phase I clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, chronic traumatic encephalopathy, and other tauopathies; Aß, or Amyloid Beta, a protein for the treatment of Alzheimer's disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegeneration. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Celgene Corporation to develop antibodies. Prothena Corporation plc was founded in 2012 and is based in Dublin, Ireland.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingProthena has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.00, Prothena has a potential upside of 35.5% from its current price of $12.55.Amount of Analyst CoverageProthena has only been the subject of 2 research reports in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesProthena has received 544 “outperform” votes. (Add your “outperform” vote.)Underperform VotesProthena has received 430 “underperform” votes. (Add your “underperform” vote.)Community SentimentProthena has received 55.85% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Prothena and other stocks. Vote “Outperform” if you believe PRTA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PRTA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldProthena does not currently pay a dividend.Dividend GrowthProthena does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Prothena insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 30.40% of the stock of Prothena is held by insiders.Percentage Held by Institutions93.08% of the stock of Prothena is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Prothena are expected to grow in the coming year, from ($2.43) to ($2.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Prothena is -6.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Prothena is -6.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProthena has a P/B Ratio of 1.83. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.59 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PRTA Previous Symbol CUSIPN/A CIK1559053 Webwww.prothena.com Phone011-353-1236-2500Debt Debt-to-Equity Ratio0.06 Current Ratio21.05 Quick Ratio21.05Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$810,000.00 Price / Sales618.36 Cash FlowN/A Price / Cash FlowN/A Book Value$6.84 per share Price / Book1.83Profitability EPS (Most Recent Fiscal Year)($1.95) Net Income$-77,680,000.00 Net Margins-10,452.67% Return on Equity-28.71% Return on Assets-18.57%Miscellaneous Employees59 Outstanding Shares39,910,000Market Cap$500.87 million Next Earnings Date8/6/2020 (Confirmed) OptionableOptionable $12.55 -0.21 (-1.65 %) (As of 08/4/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive PRTA News and Ratings via Email Sign-up to receive the latest news and ratings for PRTA and its competitors with MarketBeat's FREE daily newsletter. Prothena (NASDAQ:PRTA) Frequently Asked Questions How has Prothena's stock been impacted by COVID-19 (Coronavirus)? Prothena's stock was trading at $9.72 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PRTA shares have increased by 29.1% and is now trading at $12.55. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Prothena? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prothena in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Prothena. When is Prothena's next earnings date? Prothena is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Prothena. How were Prothena's earnings last quarter? Prothena Co. PLC (NASDAQ:PRTA) posted its quarterly earnings results on Wednesday, May, 6th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.57) by $0.02. The biotechnology company had revenue of $0.14 million for the quarter, compared to analysts' expectations of $0.23 million. Prothena had a negative net margin of 10,452.67% and a negative return on equity of 28.71%. View Prothena's earnings history. What price target have analysts set for PRTA? 4 brokerages have issued 1 year price objectives for Prothena's stock. Their forecasts range from $14.00 to $19.00. On average, they anticipate Prothena's share price to reach $17.00 in the next twelve months. This suggests a possible upside of 35.5% from the stock's current price. View analysts' price targets for Prothena. Has Prothena been receiving favorable news coverage? Media coverage about PRTA stock has trended somewhat negative this week, InfoTrie reports. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Prothena earned a daily sentiment score of -1.0 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the stock's share price in the immediate future. View the latest news about Prothena. Who are some of Prothena's key competitors? Some companies that are related to Prothena include Ligand Pharmaceuticals (LGND), Prestige Consumer Healthcare (PBH), Uniqure (QURE), Aurinia Pharmaceuticals (AUPH), Xencor (XNCR), Corcept Therapeutics (CORT), I-Mab (IMAB), Dicerna Pharmaceuticals (DRNA), INDIVIOR PLC/S (INVVY), Madrigal Pharmaceuticals (MDGL), IGM Biosciences (IGMS), Eidos Therapeutics (EIDX), Ironwood Pharmaceuticals (IRWD), Intercept Pharmaceuticals (ICPT) and Heron Therapeutics (HRTX). View all competitors. What other stocks do shareholders of Prothena own? Based on aggregate information from My MarketBeat watchlists, some companies that other Prothena investors own include Canopy Growth (CGC), Cara Therapeutics (CARA), Actinium Pharmaceuticals (ATNM), ArcelorMittal (MT), Merck & Co., Inc. (MRK), BIOLINERX LTD/S (BLRX), Energous (WATT), Gilead Sciences (GILD), ACADIA Pharmaceuticals (ACAD) and Perrigo (PRGO). Who are Prothena's key executives? Prothena's management team includes the following people: Mr. Gene G. Kinney, Pres, CEO & Director (Age 50)Mr. Tran B. Nguyen, CFO & COO (Age 45)Mr. Arthur W. Homan, Chief Legal Officer & Company Sec. (Age 60)Ms. Karin L. Walker, Chief Accounting Officer & Controller (Age 56)Dr. Wagner M. Zago, Chief Scientific Officer (Age 46) What is Prothena's stock symbol? Prothena trades on the NASDAQ under the ticker symbol "PRTA." Who are Prothena's major shareholders? Prothena's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Campbell & CO Investment Adviser LLC (0.09%), Diversified Trust Co (0.03%), SG Americas Securities LLC (0.03%) and ProShare Advisors LLC (0.03%). View institutional ownership trends for Prothena. Which institutional investors are selling Prothena stock? PRTA stock was sold by a variety of institutional investors in the last quarter, including SG Americas Securities LLC. View insider buying and selling activity for Prothena. Which institutional investors are buying Prothena stock? PRTA stock was purchased by a variety of institutional investors in the last quarter, including Campbell & CO Investment Adviser LLC, Diversified Trust Co, and ProShare Advisors LLC. View insider buying and selling activity for Prothena. How do I buy shares of Prothena? Shares of PRTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Prothena's stock price today? One share of PRTA stock can currently be purchased for approximately $12.55. How big of a company is Prothena? Prothena has a market capitalization of $500.87 million and generates $810,000.00 in revenue each year. The biotechnology company earns $-77,680,000.00 in net income (profit) each year or ($1.95) on an earnings per share basis. Prothena employs 59 workers across the globe. What is Prothena's official website? The official website for Prothena is www.prothena.com. How can I contact Prothena? Prothena's mailing address is 77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS, DUBLIN L2, D02 T804. The biotechnology company can be reached via phone at 011-353-1236-2500 or via email at [email protected] This page was last updated on 8/5/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
